Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction (FAIR-HFpEF)
Effect of IV Iron (Ferric Carboxymaltose, Ferinject) on Exercise Tolerance, Symptoms and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and Iron Deficiency With and Without Anaemia.
Sponsor: Charite University, Berlin, Germany
Listed as NCT03074591, this PHASE4 trial focuses on Heart Failure and Iron-deficiency and remains completed. Sponsored by Charite University, Berlin, Germany, it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE4
Status: Unknown Status → Completed · Phase: PHASE2 → PHASE4
-
Apr 2022 — Jun 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 7 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Sep 2019 — Feb 2020 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Sep 2019 [monthly]
Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
May 2017 — Sep 2017 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Charite University, Berlin, Germany
- University of Göttingen
For direct contact, visit the study record on ClinicalTrials.gov .